Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 52Carcinoma, Renal Cell 25Liver Neoplasms 23Neoplasms 19Carcinoma, Non-Small-Cell Lung 16Breast Neoplasms 16Kidney Neoplasms 11Leukemia, Myeloid, Acute 9Melanoma 8Glioblastoma 8Sarcoma 7Prostatic Neoplasms 7Neoplasm Metastasis 7Brain Neoplasms 7Thyroid Neoplasms 6Ovarian Neoplasms 6Lung Neoplasms 6Pancreatic Neoplasms 5Gliosarcoma 5Urinary Bladder Neoplasms 4Recurrence 4Leukemia, Myelomonocytic, Chronic 4Leukemia 4Carcinoma 4Rectal Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Multiple Myeloma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leiomyosarcoma 3

Interventions

bintrafusp alfa protein, human 2Radiotherapy 2Cisplatin 2fresolimumab 1enzalutamide 1Sorafenib 1Paclitaxel 1LY-2157299 1Gemcitabine 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Camurati-Engelmann Syndrome × Sorafenib × Clear all
NCT02178358 2022-02-25

A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma

Eli Lilly and Company

Phase 2 Completed
132 enrolled 25 charts
Gastrointestinal

Camurati-Engelmann Syndrome, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡